Snyder, Claire http://orcid.org/0000-0001-8952-4561
Hannum, Susan M.
White, Sharon
Montanari, Amanda
Ikejiani, Dara
Smith, Benjamin
Blackford, Amanda
Thorner, Elissa
Smith, Katherine C.
Carducci, Michael A.
Stearns, Vered http://orcid.org/0000-0003-4018-4708
Smith, Karen Lisa http://orcid.org/0000-0002-6687-0119
Funding for this research was provided by:
Maryland Department of Health and Mental Hygiene
National Cancer Institute (P30CA006973)
Article History
Accepted: 13 January 2022
First Online: 8 February 2022
Declarations
:
: Dr. Snyder has funding from Pfizer and Genentech through the institution and consults to Janssen via Health Outcomes Solutions. Ms. Thorner reports funding from Pfizer and Genentech. Dr. Stearns received research grants to institution from Abbvie, Biocept, Pfizer, Novartis, and Puma Biotechnology and is a Data Safety Monitoring Board member for Immunomedics, Inc. Dr. Karen Smith has received research funding through the institution from Pfizer and has a family member with stock in Abbott Laboratories and Abbvie. Dr. Katherine Smith, Dr. Hannum, Dr. Carducci, Ms. White, Ms. Blackford, Ms. Montanari, Ms. Ikejiani, and Mr. Smith report no conflicts or competing interests.
: These studies were reviewed and approved by the Johns Hopkins School of Medicine Institutional Review Board and performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: For the qualitative interviews, all participants underwent an IRB-approved oral consent process. For the feasibility study, patients provided written informed consent; the IRB waived documentation of consent for the clinician co-investigator end-of-study interviews. The waiver of consent document was included with the email invitation, and the interview script specified that completion of the interview represented consent to participate.
: Not applicable.
Free to read: This content has been made available to all.